After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna expects many new products to launch in just a few years, so it's possible that in 10 years, Moderna could have about 10 products on the market.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The FDA's Dr. Vinay Prasad said that he disagreed with the agency's career vaccine reviewers about COVID shot approvals.

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals and sickening people.

The decision to cancel the Moderna contracts, undoubtedly driven by anti-vaccine crusader and HHS Secretary Robert F. Kennedy, Jr., puts the entire nation at risk, as does this administration’s ...